Volastra
Volastra develops therapeutics for cancer treatment, focusing on compounds that target chromosomal instability and related pathways to inhibit genomic instability and disease progression. The company is also developing proprietary imaging technologies to identify chromosomal instability cancers for patient stratification. Founded in 2019 and headquartered in New York City, Volastra has raised approximately $117.3M…
Funding snapshot
About
Volastra develops therapeutics for cancer treatment, focusing on compounds that target chromosomal instability and related pathways to inhibit genomic instability and disease progression. The company is also developing proprietary imaging technologies to identify chromosomal instability cancers for patient stratification. Founded in 2019 and headquartered in New York City, Volastra has raised approximately $117.3M in Series B funding from investors including Polaris Partners, Droia, Arch Venture Partners, Vida Ventures, Catalio Capital Management, Lilly, Cornell University, and B Capital. The company targets chromosomal instability, a hallmark of aggressive cancers that drives tumor evolution, metastasis, and therapy resistance. By developing drugs that specifically address the mechanisms underlying chromosomal instability, Volastra aims to create new treatment options for patients with cancers that have limited therapeutic alternatives, particularly in indications where chromosomal instability drives poor outcomes.
Business model
Oncology > Drugs > Pan Cancer,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.